Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome.
Adolescent
Adult
B-Lymphocytes
/ immunology
Child
Child, Preschool
Chromosome Mapping
Cytokines
/ metabolism
Disease Susceptibility
Down Syndrome
/ genetics
Female
Gene Dosage
Gene Expression Profiling
Genetic Loci
Genetic Predisposition to Disease
Humans
Interferon Type I
/ genetics
Male
Middle Aged
Monocytes
/ immunology
Receptors, Interferon
/ genetics
STAT1 Transcription Factor
/ metabolism
T-Lymphocyte Subsets
/ immunology
Transcriptome
Young Adult
Down syndrome
JAK-STAT
interferon receptors
interferonopathy
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
15
10
2019
accepted:
04
06
2020
pubmed:
24
6
2020
medline:
14
9
2021
entrez:
24
6
2020
Statut:
ppublish
Résumé
Down syndrome (DS) is characterized by the occurrence of three copies of human chromosome 21 (HSA21). HSA21 contains a cluster of four interferon receptor (IFN-R) genes: IFNAR1, IFNAR2, IFNGR2, and IL10RB. DS patients often develop mucocutaneous infections and autoimmune diseases, mimicking patients with heterozygous gain-of-function (GOF) STAT1 mutations, which enhance cellular responses to three types of interferon (IFN). A gene dosage effect at these four loci may contribute to the infectious and autoimmune manifestations observed in individuals with DS. We report high levels of IFN-αR1, IFN-αR2, and IFN-γR2 expression on the surface of monocytes and EBV-transformed-B (EBV-B) cells from studying 45 DS patients. Total and phosphorylated STAT1 (STAT1 and pSTAT1) levels were constitutively high in unstimulated and IFN-α- and IFN-γ-stimulated monocytes from DS patients but lower than those in patients with GOF STAT1 mutations. Following stimulation with IFN-α or -γ, but not with IL-6 or IL-21, pSTAT1 and IFN-γ activation factor (GAF) DNA-binding activities were significantly higher in the EBV-B cells of DS patients than in controls. These responses resemble the dysregulated responses observed in patients with STAT1 GOF mutations. Concentrations of plasma type I IFNs were high in 12% of the DS patients tested (1.8% in the healthy controls). Levels of type I IFNs, IFN-Rs, and STAT1 were similar in DS patients with and without recurrent skin infections. We performed a genome-wide transcriptomic analysis based on principal component analysis and interferon modules on circulating monocytes. We found that DS monocytes had levels of both IFN-α- and IFN-γ-inducible ISGs intermediate to those of monocytes from healthy controls and from patients with GOF STAT1 mutations. Unlike patients with GOF STAT1 mutations, patients with DS had normal circulating Th17 counts and a high proportion of terminally differentiated CD8
Identifiants
pubmed: 32572726
doi: 10.1007/s10875-020-00803-9
pii: 10.1007/s10875-020-00803-9
pmc: PMC7418179
mid: NIHMS1606231
doi:
Substances chimiques
Cytokines
0
Interferon Type I
0
Receptors, Interferon
0
STAT1 Transcription Factor
0
STAT1 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
807-819Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK083256
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI095983
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127564
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States
Références
Acta Paediatr Scand. 1975 Mar;64(2):322-6
pubmed: 124122
J Clin Immunol. 2020 Apr;40(3):447-455
pubmed: 31993866
Nat Rev Genet. 2004 Oct;5(10):725-38
pubmed: 15510164
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24231-24241
pubmed: 31699819
J Dtsch Dermatol Ges. 2018 Oct;16(10):1289-1295
pubmed: 30300491
JAAD Case Rep. 2019 Apr 05;5(4):365-367
pubmed: 31008170
J Infect Chemother. 2015 Nov;21(11):790-4
pubmed: 26386776
Acta Derm Venereol. 2019 Mar 1;99(3):351-352
pubmed: 30460373
Hum Mol Genet. 2013 Feb 15;22(4):769-81
pubmed: 23161749
J Nat Sci Biol Med. 2015 Jul-Dec;6(2):300-5
pubmed: 26283817
BMC Pediatr. 2017 Jan 31;17(1):41
pubmed: 28143429
Nat Rev Drug Discov. 2007 Dec;6(12):975-90
pubmed: 18049472
J Exp Med. 2017 May 1;214(5):1547-1555
pubmed: 28420733
Am J Hum Genet. 2007 Aug;81(2):252-63
pubmed: 17668376
J Pediatr. 2005 Dec;147(6):744-7
pubmed: 16356423
Nature. 2014 Apr 17;508(7496):345-50
pubmed: 24740065
Nat Genet. 1995 Oct;11(2):177-84
pubmed: 7550346
Br J Dermatol. 2002 Jul;147(1):37-40
pubmed: 12100182
Science. 1974 Oct 4;186(4158):61-3
pubmed: 4371269
Ear Nose Throat J. 2008 Jan;87(1):34-5, 43
pubmed: 18357944
Mycoses. 2004 Apr;47(3-4):131-5
pubmed: 15078429
Nat Cell Biol. 2016 Mar;18(3):246-54
pubmed: 26911908
J Exp Med. 2011 Aug 1;208(8):1635-48
pubmed: 21727188
Spec Care Dentist. 2011 Nov-Dec;31(6):197-203
pubmed: 22070358
Blood. 2010 Dec 23;116(26):5895-906
pubmed: 20841510
Rev Paul Pediatr. 2017 Jul-Sep;35(3):361-364
pubmed: 28977299
Front Immunol. 2017 Feb 28;8:119
pubmed: 28293236
Am J Med Genet A. 2017 Jun;173(6):1539-1545
pubmed: 28332275
Blood. 2016 Jun 23;127(25):3154-64
pubmed: 27114460
PLoS One. 2014 May 12;9(5):e96868
pubmed: 24818963
Clin Exp Dermatol. 2006 Sep;31(5):623-9
pubmed: 16901300
Clin Exp Immunol. 2011 Apr;164(1):9-16
pubmed: 21352207
Cell. 2016 Jul 28;166(3):582-595
pubmed: 27426947
Genet Med. 2017 Apr;19(4):439-447
pubmed: 27608174
Immunity. 2013 Apr 18;38(4):831-44
pubmed: 23601689
Braz J Infect Dis. 2013 Sep-Oct;17(5):624-5
pubmed: 23911099
Immunity. 2008 Jul 18;29(1):150-64
pubmed: 18631455
J Exp Med. 2016 Nov 14;213(12):2527-2538
pubmed: 27821552
C R Hebd Seances Acad Sci. 1959 Mar 16;248(11):1721-2
pubmed: 13639368
Curr Opin Allergy Clin Immunol. 2012 Dec;12(6):616-22
pubmed: 23026768
N Engl J Med. 2011 Jul 7;365(1):54-61
pubmed: 21714643
Hum Mol Genet. 2010 Feb 1;19(3):434-44
pubmed: 19880857
AJR Am J Roentgenol. 2004 Jul;183(1):175-81
pubmed: 15208134
Lancet Neurol. 2013 Dec;12(12):1159-69
pubmed: 24183309
Nature. 1977 May 12;267(5607):165-7
pubmed: 16073432
Elife. 2016 Jul 29;5:
pubmed: 27472900
J Med Genet. 1989 Dec;26(12):764-8
pubmed: 2533264
J Exp Med. 2003 Mar 17;197(6):711-23
pubmed: 12642603